Comment
doi: 10.1158/1078-0432.CCR-13-2234.
Epub 2013 Sep 18.
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response
Affiliations
- PMID: 24048329
- PMCID: PMC6101650
- DOI: 10.1158/1078-0432.CCR-13-2234
Item in Clipboard
Comment
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response
Clin Cancer Res.
.
No abstract available
Conflict of interest statement
Disclosure of Potential Conflicts of Interest:
M. Sznol is a consultant/advisory board member of Bristol-Myers Squibb, Genesis Biopharma, and MedImmune. No potential conflicts of interest were disclosed by the other author.
Comment on
-
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.Clin Cancer Res. 2013 Mar 1;19(5):1021-34. doi: 10.1158/1078-0432.CCR-12-2063. Clin Cancer Res. 2013. PMID: 23460533 Free PMC article.
-
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter.Clin Cancer Res. 2013 Oct 1;19(19):5541. doi: 10.1158/1078-0432.CCR-13-1054. Epub 2013 Sep 18. Clin Cancer Res. 2013. PMID: 24048330 Free PMC article. No abstract available.
Similar articles
-
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--letter.Clin Cancer Res. 2013 Oct 1;19(19):5541. doi: 10.1158/1078-0432.CCR-13-1054. Epub 2013 Sep 18. Clin Cancer Res. 2013. PMID: 24048330 Free PMC article. No abstract available.
-
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.Clin Cancer Res. 2013 Mar 1;19(5):1021-34. doi: 10.1158/1078-0432.CCR-12-2063. Clin Cancer Res. 2013. PMID: 23460533 Free PMC article.
-
Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy.Signal Transduct Target Ther. 2020 Aug 24;5(1):158. doi: 10.1038/s41392-020-00254-z. Signal Transduct Target Ther. 2020. PMID: 32839442 Free PMC article. No abstract available.
-
PD-1/PD-L1 and immunotherapy for pancreatic cancer.Cancer Lett. 2017 Oct 28;407:57-65. doi: 10.1016/j.canlet.2017.08.006. Epub 2017 Aug 18. Cancer Lett. 2017. PMID: 28826722 Review.
-
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.Int J Mol Sci. 2017 Jun 21;18(6):1331. doi: 10.3390/ijms18061331. Int J Mol Sci. 2017. PMID: 28635644 Free PMC article. Review.
Cited by
-
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.Immunotherapy. 2016 Jun;8(7):821-37. doi: 10.2217/imt-2016-0002. Immunotherapy. 2016. PMID: 27349981 Free PMC article. Review.
-
Durable Response After Combination Of Concurrent Chemoradiotherapy And Anti-PD-1 Therapy In HER2-Negative Advanced Gastric Adenocarcinoma: A Case Report.Onco Targets Ther. 2019 Sep 19;12:7691-7698. doi: 10.2147/OTT.S221436. eCollection 2019. Onco Targets Ther. 2019. PMID: 31571920 Free PMC article.
-
Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types.Onco Targets Ther. 2015 Apr 22;8:929-37. doi: 10.2147/OTT.S53164. eCollection 2015. Onco Targets Ther. 2015. PMID: 25960664 Free PMC article. Review.
-
Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.Int J Mol Sci. 2019 Jan 4;20(1):158. doi: 10.3390/ijms20010158. Int J Mol Sci. 2019. PMID: 30621125 Free PMC article. Review.
-
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.Nat Rev Drug Discov. 2022 Jul;21(7):529-540. doi: 10.1038/s41573-022-00493-5. Epub 2022 Jun 14. Nat Rev Drug Discov. 2022. PMID: 35701637 Review.
References
-
- Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8:793–800. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
